- Conditions
- HIV, Coronary Artery Disease
- Interventions
- metformin extended release
- Drug
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mild Cognitive Impairment
- Interventions
- Placebo oral tablet, extended release metformin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 22
- States / cities
- Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Healthy
- Interventions
- Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Asthma, Asthma Chronic, Overweight and Obesity
- Interventions
- Metformin hydrochloride extended-release tablets, Visually identical placebo Metformin hydrochloride extended-release tablets
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Houston, Texas
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Metformin, Dietary Restriction, Exercise Training
- Drug · Behavioral
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Healthy
- Interventions
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Healthy
- Interventions
- 1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Metformin Adverse Reaction, Tolerance
- Interventions
- Metformin Extended Release Oral Tablet, Placebo oral capsule
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more
- Conditions
- NIDDM, Obesity
- Interventions
- Metformin Extended Release (ER) Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Metformin XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
- Conditions
- Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
- Interventions
- Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
- Interventions
- metformin, pioglitazone, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota